SecBot SecBot
6-K ·Filed Apr 13, 2026

GSK

GSK plc
NEUTRAL
Impact 3/10
Horizondays Processed7mo ago SEC0001654954-26-003420
Notable filing: 6-K
Actionable Insight • Neutral

The share repurchase is a routine execution of GSK's announced buyback program and does not signal any change in strategy. Traders should monitor for larger cumulative buyback volumes over time rather than reacting to individual daily transactions.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$58.94
T+0 close · Apr 13, 2026 · via day close
Latest settled
−10.89%
T+60 · $52.52
Vs SPY
−19.82%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 13 $58.94entry
  2. T+1 · 7mo ago +0.41%α −0.80% · $59.18
  3. T+5 · 7mo ago −2.70%α −5.99% · $57.35
  4. T+20 · 6mo ago −15.49%α −23.22% · $49.81
  5. T+60 · 4mo ago −10.89%α −19.82% · $52.52
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK plc repurchased 325,000 ordinary shares on April 10, 2026, as part of its ongoing buyback program, at a volume-weighted average price of 2,182.28 GBp. This transaction increases the company's treasury shares to 258.1 million, representing 6.36% of voting rights.

Key Facts

  • GSK repurchased 325,000 ordinary shares on April 10, 2026
  • Purchase price ranged from 2,157.00p to 2,196.00p per share, with a volume-weighted average of 2,182.28p
  • Shares were purchased through BNP Paribas SA on multiple exchanges
  • Total treasury shares now stand at 258,112,615, or 6.36% of voting rights
  • The repurchase is part of an existing buyback program announced on February 17, 2026

Financial Impact

The repurchase represents a nominal investment of approximately £709 million (325,000 shares × 2,182.28 GBp), though the exact amount is not disclosed in the filing.

shares outstandingtreasury stockvoting rights

Risk Factors

  • The buyback could accelerate if the company has excess cash, potentially reducing capital available for R&D or acquisitions
  • Continued repurchases may limit downside protection if the stock price declines

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-003420
Document: 0001654954-26-003420-index-headers.html0001654954-26-003420
Document: 0001654954-26-003420-index.html0001654954-26-003420
Document: 0001654954-26-003420.txt0001654954-26-003420

US Market Status

Market Closed · Opens Wed (10h 11m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026